Streetbeat News

Price Targets

RCKT

Cantor Fitzgerald analyst Josh Schimmer has initiated coverage on Rocket Pharmaceuticals (NASDAQ:RCKT) with an Overweight rating and a price target of $65.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 9:07 am

BBIO

Cantor Fitzgerald analyst Josh Schimmer has initiated coverage on BridgeBio Pharma (NASDAQ:BBIO) with an Overweight rating and a price target of $50.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 9:01 am

MIRM

Cantor Fitzgerald analyst Joshua Schimmer has initiated coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) with an Overweight rating and a price target of $50.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 8:59 am

KRYS

Cantor Fitzgerald analyst Josh Schimmer has initiated coverage on Krystal Biotech (NASDAQ:KRYS) with an Overweight rating and a price target of $160.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 8:57 am

CABA

Cantor Fitzgerald analyst Joshua Schimmer has initiated coverage on Cabaletta Bio (NASDAQ:CABA) with an Overweight rating and a price target of $40.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 8:55 am

TTD

Loop Capital analyst Rob Sanderson has initiated coverage on Trade Desk (NASDAQ:TTD) with a Buy rating and a price target of $95.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 8:48 am

CLPT

Stifel analyst Mathew Blackman has initiated coverage on ClearPoint Neuro (NASDAQ:CLPT) with a Buy rating and a price target of $8.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 8:46 am

FMC

Goldman Sachs analyst Adam Samuelson has downgraded FMC (NYSE:FMC) from Buy to Neutral and lowered the price target from $135 to $59.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 8:41 am

FMC

B of A Securities analyst Steve Byrne has downgraded FMC (NYSE:FMC) from Buy to Neutral and announced a price target of $63.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 8:38 am

BRZE

DA Davidson analyst Gil Luria has upgraded Braze (NASDAQ:BRZE) from Neutral to Buy and set a price target of $53.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 8:32 am